Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
First Claim
1. A recombinant anti-CD 137 antibody encoded by a transgene DNA construct in a first bioreactor organism comprising a polypeptide domain which is bioactive in a target animal when produced by said first bioreactor organism.
5 Assignments
0 Petitions
Accused Products
Abstract
The current invention relates to the development and methods of use of a recombinant agonistic antibody anti-human CD137, and glycosylation variants thereof. These antibodies act as an anti-cancer agents and/or immune modulators that are effective in shrinking solid tumors or other cancerous indications and preventing their recurrence. The types of cancer for which the contemplated antibody is effective in treating also include leukemia and lymphoma. In a preferred imbodiment the recombinant antibodies of the current invention were produced in and purified from the milk of transgenic animals.
-
Citations
28 Claims
- 1. A recombinant anti-CD 137 antibody encoded by a transgene DNA construct in a first bioreactor organism comprising a polypeptide domain which is bioactive in a target animal when produced by said first bioreactor organism.
-
17. A method for the production of transgenic animals capable of producing a transgenic antibody of interest comprising:
-
transfecting a non-human mammalian cell-line with a transgene DNA construct encoding a desired transgenic antibody;
selecting a cell line(s) in which said transgene DNA construct has been inserted into the genome of that cell or cell-line; and
performing a first nuclear transfer procedure to generate a first transgenic animal heterozygous for the desired gene said animal being capable of expressing said transgenic antibody of interest in its milk. - View Dependent Claims (18)
-
-
23. A method for depleting double negative T-cells in a subject, said method comprising:
-
(a) identifying a subject as being in need of depletion of double negative T cells; and
(b) administering to said subject an effective amount of a recombinant agonist anti CD 137 antibody. - View Dependent Claims (25, 26, 27)
-
-
24. The method of claim 24, wherein said subject is a human.
Specification